Cytogenetics and Molecular Biology Laboratory, Department of Zoology, University of Kalyani, Kalyani-741 235, Institute of Genetic Engineering, 30 Thakurhat Road, Badu, Kolkata-700 128, Directorate of Research, Bidhan Chandra Krishi Viswavidyalaya, Kalyani, West Bengal, India and Boiron Laboratory, 20 Rue de la Liberation, Sainte-Foy-Les-Lyon, France.
Evid Based Complement Alternat Med. 2010 Mar;7(1):129-36. doi: 10.1093/ecam/nem161. Epub 2007 Oct 29.
Several homeopathic remedies, namely, Pulsatilla Nigricans (30th potency), Ceanothus Americanus (both mother tincture and 6th potency) and Ferrum Metallicum (30th potency) selected as per similia principles were administered to 38 thalassemic patients receiving Hydroxyurea (HU) therapy for a varying period of time. Levels of serum ferritin (SF), fetal hemoglobin (HbF), hemoglobin (Hb), platelet count (PC), mean corpuscular volume (MCV), mean corpuscular hemoglobin concentration (MCHC), mean corpuscular hemoglobin (MCH), white blood cell (WBC) count, bilirubin content, alanine amino transferase (ALT), aspartate amino transferase (AST) and serum total protein content of patients were determined before and 3 months after administration of the homeopathic remedies in combination with HU to evaluate additional benefits, if any, derived by the homeopathic remedies, by comparing the data with those of 38 subjects receiving only HU therapy. Preliminary results indicated that there was a significant decrease in the SF and increase in HbF levels in the combined, treated subjects. Although the changes in other parameters were not so significant, there was a significant decrease in size of spleen in most patients with spleenomegaly and improvement in general health conditions along with an increased gap between transfusions in most patients receiving the combined homeopathic treatment. The homeopathic remedies being inexpensive and without any known side-effects seem to have great potentials in bringing additional benefits to thalassemic patients; particularly in the developing world where blood transfusions suffer from inadequate screening and fall short of the stringent safety standards followed in the developed countries. Further independent studies are encouraged.
几种顺势疗法药物，即黑种草（30 号潜能）、美洲金缕梅（母酊剂和 6 号潜能）和硫酸亚铁（30 号潜能），根据相似性原则选择，用于 38 名接受羟基脲（HU）治疗的地中海贫血患者，治疗时间长短不一。在联合使用 HU 给予顺势疗法药物治疗 3 个月前后，测定患者的血清铁蛋白（SF）、胎儿血红蛋白（HbF）、血红蛋白（Hb）、血小板计数（PC）、平均红细胞体积（MCV）、平均红细胞血红蛋白浓度（MCHC）、平均红细胞血红蛋白（MCH）、白细胞（WBC）计数、胆红素含量、丙氨酸氨基转移酶（ALT）、天冬氨酸氨基转移酶（AST）和血清总蛋白含量，以评估顺势疗法药物的额外益处，如果有的话，并将数据与仅接受 HU 治疗的 38 名受试者的数据进行比较。初步结果表明，联合治疗组 SF 显著降低，HbF 水平显著升高。尽管其他参数的变化不那么显著，但大多数脾肿大患者的脾脏大小明显缩小，一般健康状况改善，大多数接受联合顺势疗法治疗的患者的输血间隔增大。顺势疗法药物价格低廉，没有已知的副作用，似乎对地中海贫血患者有很大的益处；特别是在发展中国家，那里的输血因缺乏充分的筛查而无法达到发达国家遵循的严格安全标准。鼓励进行进一步的独立研究。
